métodos para produzir partículas virais com glicosilação simplificada de proteínas de superfície.

    公开(公告)号:BR112013011198A2

    公开(公告)日:2016-07-05

    申请号:BR112013011198

    申请日:2011-11-04

    Abstract: métodos para produzir partículas virais com glicosilação simplificada de proteínas de superfície. os métodos para a produção de partículas de vírus com a glicosilação simplificada em proteínas estruturais ou de superfície são fornecidos. quando usados como alvos para a produção de vacinas, a natureza conservada de tais locais gera vacinas que são menos sensíveis às mutações virais. o uso de inibidores de glicosilação para a produção de vírus com perfis de glicosilação simplificados são divulgados. uma divulgação exemplar dos vírus influenza e métodos para a produção de partículas de vírus influenza monoglicosilado ser fornecido. os métodos para a produção de formas de monoglicosilado de vírus influenza a, nibrg-14 (h5n1) são fornecidos.

    Methods and compositions for immunization against virus

    公开(公告)号:AU2016203431A1

    公开(公告)日:2016-06-16

    申请号:AU2016203431

    申请日:2016-05-25

    Abstract: METHODS AND COMPOSITIONS FOR IMMUNIZATION AGAINST Immunogenic compositions comprising partially glycosylated viral glycoproteins for use as vaccines against viruses are provided. Vaccines formulated using mono-, di-, or tri-glycosylated viral surface glycoproteins and polypeptides provide potent and broad protection against viruses, even across strains. Pharmaceutical compositions comprising monoglycosylated hemagglutinin polypeptides and vaccines generated therefrom and methods of their use for prophylaxis or treatment of viral infections are disclosed. Methods and compositions are disclosed for influenza virus HA, NA and M2, RSV proteins F, G and SH, Dengue virus glycoproteins M or E, hepatitis C virus glycoprotein El or E2 and HIV glycoproteins gp120 and gp4l.

    FUCOSIDASE FROM BACTEROIDES AND METHODS USING THE SAME

    公开(公告)号:CA2950577A1

    公开(公告)日:2015-12-03

    申请号:CA2950577

    申请日:2015-05-27

    Abstract: The present disclosure relates to an a-fucosidase having a-(1,2), a-(1,3), a-(1,4), and a-(1,6) fucosidase activity. The present disclosure also relates to the compositions comprising the a-fucosidase, and the methods of producing and using the a-fucosidase in cleaving a-(1,2), a-(1,3), a-(1,4), and/or a-(1,6)-linked fucoses in the glycoconjugates. Accordingly, the present invention provides the compositions and methods for the improved enzymatic hydrolysis of fucose in vitro. In particular, the present invention is useful for the efficient cleavage of core fucose in native glycoproteins without denaturation or functional deterioration of glycoproteins. The compositions and methods of the invention can facilitate the Fc glycoengineering of Fc fusion proteins or antibodies, such as therapeutic antibodies.

    ANTI-TNF-ALPHA GLYCOANTIBODIES AND USES THEREOF

    公开(公告)号:CA2950433A1

    公开(公告)日:2015-12-03

    申请号:CA2950433

    申请日:2015-05-27

    Abstract: The present disclosure relates to a novel class of anti-TNFa monoclonal antibodies or antigen binding fragments comprising a homogeneous population of anti-TNFa IgG molecules having the same N-glycan on each of Fc. The antibodies of the invention can be produced from anti-TNFa monoclonal antibodies by Fc glycoengineering. The glycoantibodies of the invention may have improved therapeutic values compared to the corresponding monoclonal antibodies that have not been glycoengineered.

    AGENTES ANTI - INFLUENZA CONJUGADOS CON ACTIVIDAD ANTI - INFLAMATORIA MEJORADOS.

    公开(公告)号:MX2014012413A

    公开(公告)日:2015-08-07

    申请号:MX2014012413

    申请日:2013-04-12

    Abstract: Se describen novedosos fármacos anti-influenza bi-funcionales, de doble enfoque, formados mediante conjugación con agentes anti-inflamatorios. Fármacos ejemplares de acuerdo con la invención incluyen conjugados de zanamivir (ZA) que porta ácido cafeico (CA) ZA-7-CA (1), ZA-7-CA-amida (7) y ZA-7-Nap (43) para inhibición simultánea de neuraminidasa de virus de influenza y supresión de citosinas proinflamatorias. Se proporcionan métodos sintéticos para la preparación de estos fármacos conjugados anti-influenza mejorados. Los conjugados de ZA bifuncionales sintéticos actúan sinérgicamente hacia la protección de ratones infectados letalmente por virus de influenza H1N1 o H5N1. La eficacia de conjugados ZA-7-CA, ZA-7-CA-amida y ZA-7-Nap es mucho mayor que la terapia de combinación de ZA con agentes anti-inflamatorios.

Patent Agency Ranking